PMID- 34359097
OWN - NLM
STAT- MEDLINE
DCOM- 20220203
LR  - 20220203
IS  - 1742-7843 (Electronic)
IS  - 1742-7835 (Linking)
VI  - 129
IP  - 5
DP  - 2021 Nov
TI  - Short- and long-term effects of fluticasone furoate/vilanterol in exercising 
      asthmatic adolescents: A randomized and open label trial.
PG  - 369-375
LID - 10.1111/bcpt.13640 [doi]
AB  - PURPOSE: Relvar(R) (fluticasone furoate [FF]/vilanterol [VI]) is a once-daily 
      inhaler with bronchodilator effect lasting 24 h. Our aim was to investigate the 
      short- and long-term effects of FF/VI on exercise-induced asthma (EIA) in 
      adolescents. METHODS: Ninety-three adolescent asthmatics aged 12-18 years were 
      referred for evaluation of EIA. Following a positive exercise challenge test 
      (ECT), 22/44 were allocated to a single administration of salbutamol (400 mug) and 
      22/44 to FF/VI (92/22 mug) in a double-blind method. Thirty-five subjects were 
      reassessed by repeat ECT 30-60 days of FF/VI. RESULTS: Median FEV(1) change 
      post-ECT at baseline was -22.8% predicted (interquartile range [IQR] -26.1 and 
      -18.0) for salbutamol and -21.0 (IQR -30.7 and -16.8) for FF/VI. Following 
      bronchodilator, FEV(1) improved similarly in both groups. Repeat ECT following 
      30-60 days of FF/VI resulted in negative ECT in 33/35 subjects; the median 
      decrease in FEV(1) of these 35 subjects was 22.6% predicted (IQR 29-18) before, 
      and 4.6% predicted (IQR 8.7-2.5) after 30-60 days of FF/VI treatment 
      (p < 0.0001). CONCLUSIONS: FF/VI is effective in reversing EIA after 15 min in 
      adolescents and in protecting EIA after 30-60 days in adolescents. Larger studies 
      are needed to assess the effect of FF/VI on EIA.
CI  - (c) 2021 Nordic Association for the Publication of BCPT (former Nordic 
      Pharmacological Society). Published by John Wiley & Sons Ltd.
FAU - Bar-Yoseph, Ronen
AU  - Bar-Yoseph R
AUID- ORCID: 0000-0002-0055-5415
AD  - Pediatric Pulmonary Institute, Ruth Children's Hospital, Rambam Health Care 
      Campus, Haifa, Israel.
AD  - Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 
      Haifa, Israel.
FAU - Gur, Michal
AU  - Gur M
AUID- ORCID: 0000-0002-9874-7617
AD  - Pediatric Pulmonary Institute, Ruth Children's Hospital, Rambam Health Care 
      Campus, Haifa, Israel.
AD  - Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 
      Haifa, Israel.
FAU - Zuckerman, Shalev
AU  - Zuckerman S
AD  - Department of Pediatrics, Ruth Children's Hospital, Rambam Health Care Campus, 
      Haifa, Israel.
FAU - Gut, Guy
AU  - Gut G
AUID- ORCID: 0000-0002-1226-4893
AD  - Pediatric Pulmonary Institute, Ruth Children's Hospital, Rambam Health Care 
      Campus, Haifa, Israel.
FAU - Hanna, Moneera
AU  - Hanna M
AD  - Pediatric Pulmonary Institute, Ruth Children's Hospital, Rambam Health Care 
      Campus, Haifa, Israel.
FAU - Toukan, Yazeed
AU  - Toukan Y
AUID- ORCID: 0000-0002-5347-1426
AD  - Pediatric Pulmonary Institute, Ruth Children's Hospital, Rambam Health Care 
      Campus, Haifa, Israel.
AD  - Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 
      Haifa, Israel.
FAU - Nir, Vered
AU  - Nir V
AUID- ORCID: 0000-0001-7279-9294
AD  - Pediatric Pulmonary Institute, Ruth Children's Hospital, Rambam Health Care 
      Campus, Haifa, Israel.
AD  - Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 
      Haifa, Israel.
FAU - Masarweh, Kamal
AU  - Masarweh K
AUID- ORCID: 0000-0003-0310-1512
AD  - Pediatric Pulmonary Institute, Ruth Children's Hospital, Rambam Health Care 
      Campus, Haifa, Israel.
FAU - Bentur, Lea
AU  - Bentur L
AUID- ORCID: 0000-0002-5503-166X
AD  - Pediatric Pulmonary Institute, Ruth Children's Hospital, Rambam Health Care 
      Campus, Haifa, Israel.
AD  - Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 
      Haifa, Israel.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210825
PL  - England
TA  - Basic Clin Pharmacol Toxicol
JT  - Basic & clinical pharmacology & toxicology
JID - 101208422
RN  - 0 (Androstadienes)
RN  - 0 (Benzyl Alcohols)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Chlorobenzenes)
RN  - 0 (Drug Combinations)
RN  - 0 (fluticasone furoate-vilanterol trifenatate)
RN  - QF8SVZ843E (Albuterol)
SB  - IM
MH  - Administration, Inhalation
MH  - Adolescent
MH  - Albuterol/*administration & dosage/pharmacology
MH  - Androstadienes/*administration & dosage/pharmacology
MH  - Asthma/*drug therapy/physiopathology
MH  - Benzyl Alcohols/*administration & dosage/pharmacology
MH  - Bronchodilator Agents/*administration & dosage/pharmacology
MH  - Child
MH  - Chlorobenzenes/*administration & dosage/pharmacology
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Exercise Test
MH  - Female
MH  - Forced Expiratory Volume/drug effects
MH  - Humans
MH  - Male
MH  - Nebulizers and Vaporizers
MH  - Prospective Studies
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Relvar
OT  - exercise challenge test
OT  - exercise-induced asthma
OT  - exercise-induced bronchoconstriction
OT  - fluticasone furoate (FF)/vilanterol (VI)
OT  - salbutamol
EDAT- 2021/08/07 06:00
MHDA- 2022/02/04 06:00
CRDT- 2021/08/06 20:33
PHST- 2021/06/22 00:00 [revised]
PHST- 2021/04/29 00:00 [received]
PHST- 2021/07/13 00:00 [accepted]
PHST- 2021/08/07 06:00 [pubmed]
PHST- 2022/02/04 06:00 [medline]
PHST- 2021/08/06 20:33 [entrez]
AID - 10.1111/bcpt.13640 [doi]
PST - ppublish
SO  - Basic Clin Pharmacol Toxicol. 2021 Nov;129(5):369-375. doi: 10.1111/bcpt.13640. 
      Epub 2021 Aug 25.